Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Leases: 2019-2022

Historic Capital Leases for Rhythm Pharmaceuticals (RYTM) over the last 2 years, with Mar 2022 value amounting to $1.8 million.

  • Rhythm Pharmaceuticals' Capital Leases fell 25.98% to $1.8 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.8 million, marking a year-over-year decrease of 25.98%. This contributed to the annual value of $1.9 million for FY2021, which is N/A change from last year.
  • As of Q1 2022, Rhythm Pharmaceuticals' Capital Leases stood at $1.8 million, which was down 8.43% from $1.9 million recorded in Q4 2021.
  • Over the past 5 years, Rhythm Pharmaceuticals' Capital Leases peaked at $3.4 million during Q1 2019, and registered a low of $1.8 million during Q1 2022.
  • In the last 3 years, Rhythm Pharmaceuticals' Capital Leases had a median value of $2.3 million in 2021 and averaged $2.3 million.
  • Data for Rhythm Pharmaceuticals' Capital Leases shows a maximum YoY fell of 25.98% (in 2022) over the last 5 years.
  • Rhythm Pharmaceuticals' Capital Leases (Quarterly) stood at $3.1 million in 2019, then decreased by 16.16% to $2.7 million in 2020, then fell by 21.84% to $1.9 million in 2021, then declined by 25.98% to $1.8 million in 2022.
  • Its last three reported values are $1.8 million in Q1 2022, $1.9 million for Q4 2021, and $2.1 million during Q3 2021.